Search results
Added:
3 years ago
The renin–angiotensin–aldosterone system (RAAS) is an essential regulatory component of cardiovascular homeostasis that exerts its actions through hormones, angiotensin II and aldosterone, which regulate vascular tone and blood pressure by causing vasoconstriction and renal sodium and water retention.1 Abnormalities in cardiac function in heart failure (HF) activate the RAAS and sympathetic…
View more
Added:
3 years ago
Heart failure (HF) affects 1–2% of the population in developed countries and absorbs a significant amount of human and economic resources.1,2 HF is a complex syndrome characterised by a spectrum of symptoms and phenotypes: HF with preserved ejection fraction, HF with mid-range ejection fraction and HF with reduced ejection fraction (HFrEF).3 Differentiating patients according to left ventricular…
View more
Added:
5 years ago
Heart failure (HF) is a major and growing public health problem with high morbidity, mortality and costs.1 Due to the ageing the population, the mean age of patients with HF is increasing and exceeds 70 years in most developed countries. HF prevalence rises with age and exceeds 10% in people over 80.2 Older patients are more frail and have a higher risk of cardiovascular events. They also have a…
View more
Added:
3 years ago
Heart failure (HF) is associated with significant morbidity and mortality and confers a major economic burden.1 Large randomised controlled trials (RCTs) have demonstrated that inhibition of the renin–angiotensin– aldosterone and sympathetic nervous systems improve outcomes in patients with HF and a reduced left ventricular ejection fraction (HFrEF) (see Figure 1),2–9 with clinical guidelines…
View more
Added:
3 years ago
Chronic heart failure (HF) is a complex and progressive clinical syndrome resulting from any abnormality of cardiac structure or function. The American College of Cardiology Foundation/American Heart Association guideline defines HF as ‘a complex clinical syndrome that results from any structural or functional impairment of ventricular filling or ejection of blood’.1 The European Society of…
View more
Added:
3 years ago
Dear Editor,
We read, with great interest, the review article written by Oliveros et al. entitled ‘Coronavirus Disease 2019 and Heart Failure: A Multiparametric Approach’, which comprehensively summarises the clinical characteristics of cardiovascular complications associated with coronavirus disease 2019 (COVID-19) and the use of telehealth in patients with heart failure.1 This review should be…
View more
Added:
3 years ago
Heart Failure (HF) constitutes a major global health problem, evidenced by substantial morbidity and mortality, requiring enormous healthcare-related expenditure. HF is associated with high symptomatic burden, and with a relentless and progressive clinical course towards end-stage disease. A large body of epidemiological data suggests that the prognosis in HF is as poor as in advanced cancer.1…
View more
Hyperkalaemia in Heart Failure
Added:
2 years ago
Article
Added:
3 years ago
Today, natriuretic peptides are ubiquitously utilized for the diagnosis, treatment, and prognostication of heart failure in the Emergency Department, as well as inpatient and outpatient settings alike.1–5 These endogenous hormones counteract some of the most detrimental effects of heart failure. Given their clinical and physiological importance, the fact that a manuscript describing the…
View more
Added:
3 years ago
This review focuses on the implications of coronavirus disease 2019 (COVID-19) in the heart failure (HF) population. First of all, we will describe the cardiovascular implications of COVID-19 and the new practices surrounding the use of telehealth to follow up and triage patients with HF. We will then discuss the current practices supported by medical societies, the role of pharmacotherapy and,…
View more
